ArticleBiochemical genetics2026
NSUN3-Mediated ROS Accumulation Promotes Hepatocellular Carcinoma Proliferation and Activates PI3K/AKT Pathway.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling.Breast cancer research : BCR · 2026Article
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NSUN3 (NOP2/Sun RNA methyltransferase family member 3) is a gene encoding an RNA methyltransferase primarily responsible for specific methylation modifications on mitochondrial tRNA. Recent studies have indicated that aberrant expression of NSUN3 may be associated with the development of a range of tumors. UALCAN and GEPIA2 were utilized for bioinformatics analyses, while lentiviral vectors and small interfering RNA techniques were employed to create cell lines with either overexpression or silencing of NSUN3. To assess the impact of NSUN3 on hepatocellular carcinoma cells in vitro, CCK-8 assays, apoptosis assays, and cell cycle analyses were conducted. The accumulation of ROS mediated by NSUN3 was evaluated using fluorescent probes specific for ROS. Additionally, Western blotting was performed to verify transfection efficiency and to analyze the expression levels of the PI3K/AKT signaling pathway and BCL-2 protein. The findings of the current investigation indicate that NSUN3 is markedly overexpressed in HCC and is associated with a negative prognosis. The role of NSUN3 in modulating mitochondrial energy metabolism implies that its overexpression may facilitate the proliferation of HCC cells through the promotion of ROS accumulation. In contrast, the silencing of NSUN3 has been demonstrated to hinder the proliferation of HCC cells. Furthermore, the results also indicate that NSUN3 has the capacity to activate the PI3K/AKT signaling pathway, this resulted in the preliminary clarification of the molecular mechanisms at play. In summary, our research addresses the functional role of NSUN3 in HCC. The initial identification of NSUN3 suggests that it may serve as a promising target for the development of novel therapeutic strategies in the treatment of HCC.
Indexed as
Identifiers
40549115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.